Novel tissue-agnostic biomarker approaches could improve response to immunotherapy
Several studies describe pan-cancer approaches utilising the latest technology for better patient selection and outcomes
First-line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis
Change is on the horizon in the management of uveal melanoma
Novel strategies are offering the possibility of extended patient survival and durable disease control
New artificial intelligence-based biomarkers offer early insight into treatment response
Findings from four studies provide further evidence on the potential of AI-driven pathology, imaging and multiomic data to guide clinical decision-making
Is it time to shift supportive care toward digital-assisted approaches?
Recent findings show digital tools have the potential to improve the monitoring of symptoms and psychological aspects, but they should be integrated within routine clinical practice
Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC
Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer
Data from the ELEVATE and ALINA studies highlight the gains provided by adjuvant ALK therapy in patients with ALK-positive disease
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
Survival improvements observed with first-line antibody–drug conjugates in triple-negative breast cancer
TROP2-targeted ADCs, sacituzumab govitecan and datopotamab deruxtecan, meet their primary endpoints in phase III trials